3.46
-0.01(-0.29%)
Currency In USD
| Previous Close | 3.47 |
| Open | 3.42 |
| Day High | 3.48 |
| Day Low | 3.22 |
| 52-Week High | 9.5 |
| 52-Week Low | 1.61 |
| Volume | 1.46M |
| Average Volume | 2.59M |
| Market Cap | 296.14M |
| PE | -2.2 |
| EPS | -1.57 |
| Moving Average 50 Days | 4.14 |
| Moving Average 200 Days | 3.2 |
| Change | -0.01 |
If you invested $1000 in Larimar Therapeutics, Inc. (LRMR) 10 years ago, it would be worth $24.83 as of November 10, 2025 at a share price of $3.46. Whereas If you bought $1000 worth of Larimar Therapeutics, Inc. (LRMR) shares 5 years ago, it would be worth $186.32 as of November 10, 2025 at a share price of $3.46.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s Ataxia
GlobeNewswire Inc.
Sep 29, 2025 11:00 AM GMT
In 4 completed studies and the ongoing OL study, 65 participants received at least 1 dose of nomlabofusp, including 39 in the OL study, with 14 on treatment for at least 6 months and 8 for over 1 year in the OL studyIncreases in skin FXN levels with
Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia
GlobeNewswire Inc.
Sep 28, 2025 9:00 PM GMT
Conference call and webcast on Monday, September 29, 2025 at 8:00 am EDTBALA CYNWYD, Pa., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatment
Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
GlobeNewswire Inc.
Jul 31, 2025 8:15 PM GMT
BALA CYNWYD, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the closing of its previou